Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kite’s Axi-Cel CAR-T: No Adcomm, No Problem

Executive Summary

Next CAR-T in line at US FDA, Kite’s axicabtagene ciloleucel, looks headed toward an early approval with the agency confirming no panel will be scheduled, according to the firm. But the company and FDA may have benefited from an advisory committee review.

Advertisement

Related Content

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps
'Living' History: Breakthrough CAR-T Application Breaks Through In National Media
Novartis CAR-T Site Selection, Risk Management Are Model For Other Sponsors
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
FDA Pazdur's Opdivo Love Affair And Other Adventures
Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel